Compare BKKT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKKT | CRBU |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | BKKT | CRBU |
|---|---|---|
| Price | $16.71 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.00 | $8.50 |
| AVG Volume (30 Days) | ★ 1.3M | 961.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,871,476,000.00 | $9,295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.04 | $3.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 107.11 | N/A |
| 52 Week Low | $6.81 | $0.66 |
| 52 Week High | $49.79 | $3.54 |
| Indicator | BKKT | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 44.84 |
| Support Level | $9.80 | $1.63 |
| Resistance Level | $11.02 | $1.80 |
| Average True Range (ATR) | 1.31 | 0.08 |
| MACD | 1.06 | 0.02 |
| Stochastic Oscillator | 90.86 | 51.92 |
Bakkt Holdings Inc operates technology that connects the digital economy by offering a platform for crypto and redeeming loyalty points. Its institutional-grade technology platform provides a custody solution that caters to more experienced market participants to store crypto and provides consumers, businesses, and institutions with the ability to buy, sell, and store crypto in a simple, intuitive digital experience accessed via application programming interfaces (APIs) or embedded web experience and Loyalty offers a full spectrum of content that clients can make available to its customers when redeeming loyalty currencies. It generates revenue in the form of Subscription and service and Transaction revenue.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.